Brokerages expect Bellerophon Therapeutics Inc (NASDAQ:BLPH) to announce earnings per share of ($0.12) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Bellerophon Therapeutics’ earnings. Bellerophon Therapeutics reported earnings of ($0.24) per share in the same quarter last year, which would suggest a positive year over year growth rate of 50%. The firm is scheduled to report its next quarterly earnings results on Thursday, March 21st.
On average, analysts expect that Bellerophon Therapeutics will report full year earnings of ($0.47) per share for the current year. For the next financial year, analysts anticipate that the business will post earnings of ($0.52) per share. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that cover Bellerophon Therapeutics.
BLPH has been the topic of a number of recent research reports. Maxim Group initiated coverage on Bellerophon Therapeutics in a research note on Thursday, January 24th. They set a “buy” rating and a $3.00 price objective on the stock. ValuEngine lowered Bellerophon Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 20th. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target on shares of Bellerophon Therapeutics in a research note on Tuesday, January 29th. Finally, Zacks Investment Research raised Bellerophon Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 price target on the stock in a research note on Tuesday, January 1st.
A number of hedge funds and other institutional investors have recently modified their holdings of BLPH. VHCP Management III LLC purchased a new stake in Bellerophon Therapeutics during the 3rd quarter worth about $2,456,000. Renaissance Technologies LLC increased its holdings in shares of Bellerophon Therapeutics by 12.2% in the 2nd quarter. Renaissance Technologies LLC now owns 1,159,200 shares of the biotechnology company’s stock valued at $2,805,000 after acquiring an additional 126,300 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Bellerophon Therapeutics by 13.1% in the 4th quarter. Geode Capital Management LLC now owns 232,890 shares of the biotechnology company’s stock valued at $186,000 after acquiring an additional 27,027 shares during the last quarter. Vanguard Group Inc increased its holdings in shares of Bellerophon Therapeutics by 2.5% in the 3rd quarter. Vanguard Group Inc now owns 1,023,533 shares of the biotechnology company’s stock valued at $1,105,000 after acquiring an additional 25,300 shares during the last quarter. Finally, Virtu Financial LLC increased its holdings in shares of Bellerophon Therapeutics by 60.2% in the 4th quarter. Virtu Financial LLC now owns 36,708 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 13,799 shares during the last quarter. Institutional investors own 50.16% of the company’s stock.
NASDAQ BLPH traded down $0.01 on Thursday, reaching $0.66. 1,525 shares of the company were exchanged, compared to its average volume of 504,191. The firm has a market capitalization of $46.18 million, a P/E ratio of -0.73 and a beta of 0.02. Bellerophon Therapeutics has a fifty-two week low of $0.47 and a fifty-two week high of $3.30.
About Bellerophon Therapeutics
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices for the treatment of cardiopulmonary diseases. The company offers INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and has completed Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis.
Featured Article: Fundamental Analysis – How It Helps Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.